Skip to main content
padlock icon - secure page this page is secure

In Vivo and Computational Chemo-Inhibition of Peritoneal Tumor Angiogenesis Studies of a New Pyrazolyl Alcohol Derivative

Buy Article:

$106.67 + tax (Refund Policy)

The antiangiogenic effects of compound 4-(quinolin-3-yl)-1-[6-(trifluoromethyl)pyridin-2-yl]-1H-pyrazol-5-ol (P) was studied in Swiss albino mice induced with Ehrlich ascites tumor (EAT) cells. Compound P (100 μg/ml body weight) was injected intraperitoneally into EAT bearing mice for alternative days and sacrificed on 13th day. Later ascites fluid volume and cell number was estimated in experimental animals. During the experimental period body weight of the animals was monitored. Inner lining of mice peritoneal cavity was examined to determine the antiangiogenesis property. DNA fragmentation study was also carried. Molecular docking studies were carried out by standard methods against VEGF target. In this study, 4-(quinolin-3-yl)-1-[6-(trifluoromethyl)pyridin-2-yl]-1H-pyrazol-5-ol (P) exhibited antiangiogenic effect against tested animals.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: March 1, 2017

More about this publication?
  • Journal of Pharmaceutical Sciences and Pharmacology is being launched to address the disconnect among different research areas related to pharmaceutical sciences and pharmacology. The extreme specialization has resulted in compartmentalization and complete segregation of disciplines related to pharmaceutical sciences. Relating a new development in drug delivery has become difficult to be noticed by the researchers in other related disciplines like the pharmacologists and/or clinicians. The aim of this journal is to publish high quality original research work and broad reviews in all related disciplines relevant to drugs under the same umbrella. Our expectation is that it will help the researchers, scholars and scientists to put their and others' work in the bigger context resulting in enhanced interdisciplinary and integrated research effort. The journal is intended to cover all disciplines and challenges in science, technology and engineering that contribute to the development of new improved drug molecules and their uses including pharmaceutical aspects.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more